SCHEMBL15311554

SCHEMBL15311554

CCCCN(CC(C)N)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 3/20 0.41
CA12 O43570 4/20 0.37
CA1 P00915 4/20 0.37
CA9 Q16790 2/20 0.37
HDAC6 Q9UBN7 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP8 P22894 1/20 0.35
CTSK P43235 5/20 0.34
CA7 P43166 1/20 0.33
CA2 P00918 1/20 0.32
TP53 P04637 1/20 0.32
HDAC3 O15379 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25969976 1.00 CA14 (0.41) CA14CA12CA1CA9HDAC6
SCHEMBL15311557 1.00 CA14 (0.41) CA14CA12CA1CA9HDAC6
SCHEMBL567297 0.88 CA14 (0.44) CA14HDAC6HDAC1HDAC2
SCHEMBL567295 0.88 CA14 (0.44) CA14HDAC6HDAC1HDAC2
SCHEMBL25969999 0.87 CA14 (0.43) CA14CA12CA1CA9HDAC6
SCHEMBL566189 0.85 CA14 (0.40) CA14HDAC6HDAC1HDAC2
SCHEMBL566188 0.85 CA14 (0.40) CA14HDAC6HDAC1HDAC2
SCHEMBL10135562 0.85 CA14 (0.46) CA14HDAC6HDAC1HDAC2
SCHEMBL567502 0.85 CA14 (0.40) CA14HDAC6HDAC1HDAC2
SCHEMBL10135563 0.85 CA14 (0.46) CA14HDAC6HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2657227-B1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-04-27 EP disclosed
US-8883792-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2014-11-11 US disclosed
EP-2657227-A1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2013-10-30 EP disclosed
US-20130274269-A1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274269-A1 NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE SULT2A1, SULT1A1, SFPQ CA14 3869/4885CA12 3676/4885CA1 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.